<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286207</url>
  </required_header>
  <id_info>
    <org_study_id>0462 Pooled 022/025/029</org_study_id>
    <nct_id>NCT01286207</nct_id>
  </id_info>
  <brief_title>Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)</brief_title>
  <official_title>Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Protocols 022, 025, 029)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This record describes pooled data for three extension studies: MK-0462-022 (NCT00897949);
      MK-0462-025 (NCT00899379); and MK-0462-029 (NCT00897104). These studies examined the
      long-term safety and efficacy of rizatriptan used for the treatment of acute migraine and
      migraine recurrence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 1995</start_date>
  <completion_date type="Actual">May 1997</completion_date>
  <primary_completion_date type="Actual">May 1997</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Patient's Headaches With Pain Relief at 2 Hours After the Initial Dose of Test Drug</measure>
    <time_frame>2 hours after initial dose of test drug</time_frame>
    <description>Headache severity was rated on a 4-point scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain) immediately before initial dose and at 2 hours thereafter. Pain relief was defined as a reduction of headache severity from grades 2/3 at baseline to 0/1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Clinical Adverse Experiences</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Serious clinical adverse experiences (CAEs) are any adverse events (AEs) occurring at any dose that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Drug-related Clinical Adverse Experiences</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Due to Clinical Adverse Experiences</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Drug-related Lab Adverse Experiences</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) laboratory adverse experience (LAE).
A LAE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1959</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>Rizatriptan 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rizatriptan 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care at onset of migraine attack</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rizatriptan 5 mg</intervention_name>
    <description>Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
    <arm_group_label>Rizatriptan 5 mg</arm_group_label>
    <other_name>MK-0462, Maxalt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rizatriptan 10 mg</intervention_name>
    <description>Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
    <arm_group_label>Rizatriptan 10 mg</arm_group_label>
    <other_name>MK-0462, Maxalt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <description>Active standard care</description>
    <arm_group_label>Standard Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant took part in study MK-0462-022, MK-0462-025, or MK-0462-029

          -  History of migraine headache
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2011</study_first_submitted>
  <study_first_submitted_qc>January 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <results_first_submitted>May 20, 2011</results_first_submitted>
  <results_first_submitted_qc>May 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2011</results_first_posted>
  <last_update_submitted>February 13, 2015</last_update_submitted>
  <last_update_submitted_qc>February 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rizatriptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All participants that completed protocol MK-0462-022 (NCT00897949), MK-0462-025 (NCT00899379), or MK-0462-029 (NCT00897104) and consented to continue in the studies up to 12 months were included in this pooled extension data.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rizatriptan 5 mg</title>
          <description>Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
        </group>
        <group group_id="P2">
          <title>Rizatriptan 10 mg</title>
          <description>Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
        </group>
        <group group_id="P3">
          <title>Standard Care</title>
          <description>Standard care at onset of migraine attack</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="751"/>
                <participants group_id="P2" count="857"/>
                <participants group_id="P3" count="351"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="453"/>
                <participants group_id="P2" count="609"/>
                <participants group_id="P3" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="298"/>
                <participants group_id="P2" count="248"/>
                <participants group_id="P3" count="90"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Response</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rizatriptan 5 mg</title>
          <description>Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
        </group>
        <group group_id="B2">
          <title>Rizatriptan 10 mg</title>
          <description>Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
        </group>
        <group group_id="B3">
          <title>Standard Care</title>
          <description>Standard care at onset of migraine attack</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="751"/>
            <count group_id="B2" value="857"/>
            <count group_id="B3" value="351"/>
            <count group_id="B4" value="1959"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.6" lower_limit="18" upper_limit="66"/>
                    <measurement group_id="B2" value="41.1" lower_limit="18" upper_limit="65"/>
                    <measurement group_id="B3" value="40.7" lower_limit="18" upper_limit="64"/>
                    <measurement group_id="B4" value="41.2" lower_limit="18" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="643"/>
                    <measurement group_id="B2" value="727"/>
                    <measurement group_id="B3" value="300"/>
                    <measurement group_id="B4" value="1670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Patient's Headaches With Pain Relief at 2 Hours After the Initial Dose of Test Drug</title>
        <description>Headache severity was rated on a 4-point scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain) immediately before initial dose and at 2 hours thereafter. Pain relief was defined as a reduction of headache severity from grades 2/3 at baseline to 0/1.</description>
        <time_frame>2 hours after initial dose of test drug</time_frame>
        <population>All patients who took study medication and filled out their diary cards were included in the analysis of efficacy. No data were imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard care at onset of migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patient's Headaches With Pain Relief at 2 Hours After the Initial Dose of Test Drug</title>
          <description>Headache severity was rated on a 4-point scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain) immediately before initial dose and at 2 hours thereafter. Pain relief was defined as a reduction of headache severity from grades 2/3 at baseline to 0/1.</description>
          <population>All patients who took study medication and filled out their diary cards were included in the analysis of efficacy. No data were imputed.</population>
          <units>percent of headaches</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="606"/>
                <count group_id="O2" value="815"/>
                <count group_id="O3" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="55.6" upper_limit="93.8"/>
                    <measurement group_id="O2" value="89.5" lower_limit="75.0" upper_limit="98.0"/>
                    <measurement group_id="O3" value="69.6" lower_limit="46.2" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Clinical Adverse Experiences</title>
        <description>Serious clinical adverse experiences (CAEs) are any adverse events (AEs) occurring at any dose that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard care at onset of migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Clinical Adverse Experiences</title>
          <description>Serious clinical adverse experiences (CAEs) are any adverse events (AEs) occurring at any dose that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="711"/>
                <count group_id="O2" value="834"/>
                <count group_id="O3" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="698"/>
                    <measurement group_id="O2" value="817"/>
                    <measurement group_id="O3" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Drug-related Clinical Adverse Experiences</title>
        <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard care at onset of migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Drug-related Clinical Adverse Experiences</title>
          <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs.</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="711"/>
                <count group_id="O2" value="834"/>
                <count group_id="O3" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                    <measurement group_id="O2" value="456"/>
                    <measurement group_id="O3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423"/>
                    <measurement group_id="O2" value="378"/>
                    <measurement group_id="O3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Due to Clinical Adverse Experiences</title>
        <time_frame>Up to 12 months</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard care at onset of migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Due to Clinical Adverse Experiences</title>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="711"/>
                <count group_id="O2" value="834"/>
                <count group_id="O3" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued due to CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not discontinued due to CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="685"/>
                    <measurement group_id="O2" value="797"/>
                    <measurement group_id="O3" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Drug-related Lab Adverse Experiences</title>
        <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) laboratory adverse experience (LAE).
A LAE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>All patients who took study medication and had lab test(s)were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard care at onset of migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Drug-related Lab Adverse Experiences</title>
          <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) laboratory adverse experience (LAE).
A LAE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
          <population>All patients who took study medication and had lab test(s)were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="709"/>
                <count group_id="O2" value="827"/>
                <count group_id="O3" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The 'total # participants affected' w/ Other AEs DOES include subjects w/ any AE (including SAEs) &gt;1 event. The true overall # of subjects affected w/ only any NonSerious AE &gt;5% is less than the # reported, but unable to be determined for this pooled extension period.
Specific Other AEs reported DO NOT include SAEs and DO NOT include events &lt;5%</desc>
      <group_list>
        <group group_id="E1">
          <title>Rizatriptan 5 mg</title>
          <description>Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
        </group>
        <group group_id="E2">
          <title>Rizatriptan 10 mg</title>
          <description>Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)</description>
        </group>
        <group group_id="E3">
          <title>Standard Care</title>
          <description>Standard care at onset of migraine attack</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism/infarction, pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Neoplasm, thyroid, malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Hemorrhage, anal/rectal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia, inguinal</sub_title>
                <description>Body as a whole/site unspecific (SOC)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Melanoma</sub_title>
                <description>Body as a whole/site unspecific (SOC)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pain, abdominal</sub_title>
                <description>Body as a whole/site unspecific (SOC)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pain, chest</sub_title>
                <description>Body as a whole/site unspecific (SOC)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Septicimea</sub_title>
                <description>Body as a whole/site unspecific (SOC)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Surgery, abdominal</sub_title>
                <description>Body as a whole/site unspecific (SOC)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <description>Body as a whole/site unspecific (SOC)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <description>Metabolic/Nutritional/Immune (SOC)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Metabolic/Nutritional/Immune (SOC)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture, elbow, right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Fracture, hip, right</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pain, back</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pain, knee</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pain, neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Trauma, cartilage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Nervous System and Psychiatric (SOC)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <description>Nervous System and Psychiatric (SOC)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Nervous System and Psychiatric (SOC)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <description>Nervous System and Psychiatric (SOC)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <description>Nervous System and Psychiatric (SOC)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <description>Urogenital System (SOC)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <description>Urogenital System (SOC)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Hypertrophy, uterine</sub_title>
                <description>Urogenital System (SOC)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Neoplasm, breast, malignant</sub_title>
                <description>Urogenital System (SOC)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Neoplasm, uterine, benign</sub_title>
                <description>Urogenital System (SOC)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <description>Urogenital System (SOC)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <description>Urogenital System (SOC)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neoplasm, skin, malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="492" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="679" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="267" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia/fatigue</sub_title>
                <description>Body as a Whole/Site Unspecific (SOC)</description>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pain, abdominal</sub_title>
                <description>Body as a Whole/Site Unspecific (SOC)</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pain, chest</sub_title>
                <description>Body as a Whole/Site Unspecific (SOC)</description>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, back</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Nervous System and Psychiatric (SOC)</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Nervous System and Psychiatric (SOC)</description>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Nervous System and Psychiatric (SOC)</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <description>Nervous System and Psychiatric (SOC)</description>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>Nervous System and Psychiatric (SOC)</description>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Infection, respiratory, upper</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="711"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="834"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

